Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization

PLoS Neglected Tropical Diseases

Volumn 6, Issue 2, 2012, Pages

  Messer, William B ^a   Yount, Boyd ^b   Hacker, Kari E ^a   Donaldson, Eric F ^b   Huynh, Jeremy P ^b   de Silva, Aravinda M ^a   Baric, Ralph S ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ARTICLE; DENGUE VIRUS 3; GENETIC VARIABILITY; GROWTH CURVE; HUMAN; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS TITRATION; ADULT; BLOOD; DENGUE; DENGUE VIRUS; GENETICS; GENOTYPE; IMMUNOLOGY; METHODOLOGY; REVERSE GENETICS; SERODIAGNOSIS; VIROLOGY;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VIRUS; GENETIC VARIATION; GENOTYPE; HUMANS; NEUTRALIZATION TESTS; REVERSE GENETICS; VIRAL ENVELOPE PROTEINS;

EID: 84857826922     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001486     Document Type: Article

References (67)

1. Kyle JL, Harris E, (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62: 71-92.
2. Burke DS, Nisalak A, Johnson DE, Scott RM, (1988) A prospective study of dengue infections in bangkok. Am J Trop Med Hyg 38: 172-180.
3. [Anonymous], (1997) Dengue and dengue hemorrhagic fever Wallingford, Oxon, UK; New York, NY, USA CAB International Available: http://search.lib.unc.edu?R=UNCb3110999.
4. Halstead SB, (2009) Antibodies determine virulence in dengue. Ann N Y Acad Sci 1171 (Suppl 1): E48-56.
5. Rothman AL, (2010) Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 338: 83-98.
6. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, et al. (1997) Origins of dengue type 2 viruses associated with increased pathogenicity in the americas. Virology 230: 244-251.
7. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM, (2003) Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 9: 800-809.
8. Armstrong PM, Rico-Hesse R, (2001) Differential susceptibility of aedes aegypti to infection by the american and southeast asian genotypes of dengue type 2 virus. Vector Borne Zoonotic Dis 1: 159-168.
9. Armstrong PM, Rico-Hesse R, (2003) Efficiency of dengue serotype 2 virus strains to infect and disseminate in aedes aegypti. Am J Trop Med Hyg 68: 539-544.
10. Diaz FJ, Farfan-Ale JA, Olson KE, Lorono-Pino MA, Gubler DJ, et al. (2002) Genetic variation within the premembrane coding region of dengue viruses from the yucatan peninsula of mexico. Am J Trop Med Hyg 67: 93-101.
11. Guzman MG, Rosario D, Mune M, Alvarez M, Rodriguez R, et al. (1996) Genetic relatedness of the dengue 3 virus isolated in the outbreak of dengue hemorrhagic fever in nicaragua, 1994. Rev Cubana Med Trop 48: 114-117.
12. Pryor MJ, Carr JM, Hocking H, Davidson AD, Li P, et al. (2001) Replication of dengue virus type 2 in human monocyte-derived macrophages: Comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am J Trop Med Hyg 65: 427-434.
13. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR, (2008) The neglected tropical diseases of latin america and the caribbean: A review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2: e300.
14. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. (2002) Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell 108: 717-725.
15. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC, (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375: 291-298.
16. Modis Y, Ogata S, Clements D, Harrison SC, (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986-6991.
17. Mukhopadhyay S, Kuhn RJ, Rossmann MG, (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3: 13-22.
18. Sabin AB, (1952) Research on dengue during world war II. Am J Trop Med Hyg 1: 30-50.
19. Alvarez M, Pavon-Oro A, Rodriguez-Roche R, Bernardo L, Morier L, et al. (2008) Neutralizing antibody response variation against dengue 3 strains. J Med Virol 80: 1783-1789.
20. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, et al. (2010) Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 6 (3): e1000821.
21. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, et al. (2010) Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84: 10630-43.
22. Zulueta A, Martin J, Hermida L, Alvarez M, Valdes I, et al. (2006) Amino acid changes in the recombinant dengue 3 envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 121: 65-73.
23. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS, (2005) Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79: 5516-5528.
24. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, et al. (2004) Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in thailand. J Infect Dis 189: 990-1000.
25. Roehrig JT, Hombach J, Barrett AD, (2008) Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21: 123-132.
26. Lanciotti RS, Lewis JG, Gubler DJ, Trent DW, (1994) Molecular evolution and epidemiology of dengue-3 viruses. J Gen Virol 75: 65-75.
27. Amarilla AA, de Almeida FT, Jorge DM, Alfonso HL, de Castro-Jorge LA, et al. (2009) Genetic diversity of the E protein of dengue type 3 virus. Virol J 6: 113.
28. Araujo JM, Nogueira RM, Schatzmayr HG, Zanotto PM, Bello G, (2009) Phylogeography and evolutionary history of dengue virus type 3. Infect Genet Evol 9: 716-725.
29. de Mora D, Andrea LD, Alvarez M, Regato M, Fajardo A, et al. (2009) Evidence of diversification of dengue virus type 3 genotype III in the south american region. Arch Virol 154: 699-707.
30. Rodriguez-Roche R, Alvarez M, Holmes EC, Bernardo L, Kouri G, et al. (2005) Dengue virus type 3, cuba, 2000-2002. Emerg Infect Dis 11: 773-774.
31. Zhang C, Mammen MP Jr, Chinnawirotpisan P, Klungthong C, Rodpradit P, et al. (2005) Clade replacements in dengue virus serotypes 1 and 3 are associated with changing serotype prevalence. J Virol 79: 15123-15130.
32. Frieman MB, Yount B, Sims AC, Deming DJ, Morrison TE, et al. (2006) SARS coronavirus accessory ORFs encode luxury functions. Adv Exp Med Biol 581: 149-152.
33. Yount B, Roberts RS, Sims AC, Deming D, Frieman MB, et al. (2005) Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol 79: 14909-14922.
34. Becker MM, Graham RL, Donaldson EF, Rockx B, Sims AC, et al. (2008) Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A 105: 19944-19949.
35. Yount B, Roberts RS, Lindesmith L, Baric RS, (2006) Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: Engineering a recombination-resistant genome. Proc Natl Acad Sci U S A 103: 12546-12551.
36. Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, et al. (2003) Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 100: 12995-13000.
37. Yount B, Denison MR, Weiss SR, Baric RS, (2002) Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol 76: 11065-11078.
38. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, et al. (2003) Multiple sequence alignment with the clustal series of programs.- Nucleic Acids Res 31: 3497-500.
39. Christenbury JG, Aw PP, Ong SH, Schreiber MJ, Chow A, et al. (2010) A method for full genome sequencing of all four serotypes of the dengue virus. J Virol Methods 169: 202-206.
40. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM, (2009) Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. Virology 392: 103-113.
41. Kraus AA, Messer W, Haymore LB, de Silva AM, (2007) Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45: 3777-3780.
42. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, et al. (2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405-413.
43. Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS, (2004) Vaccine candidates derived from a novel infectious cDNA clone of an american genotype dengue virus type 2. BMC Infect Dis 4 doi:10.1186/1471-2334-4-39.
44. Puri B, Polo S, Hayes CG, Falgout B, (2000) Construction of a full length infectious clone for dengue-1 virus western pacific,74 strain. Virus Genes 20: 57-63.
45. Kapoor M, Zhang L, Mohan PM, Padmanabhan R, (1995) Synthesis and characterization of an infectious dengue virus type-2 RNA genome (new guinea C strain). Gene 162: 175-180.
46. Lai CJ, Zhao BT, Hori H, Bray M, (1991) Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci U S A 88: 5139-5143.
47. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, et al. (2008) The flavivirus precursor membrane-envelope protein complex: Structure and maturation. Science 319: 1830-1834.
48. Kochel TJ, Watts DM, Halstead SB, Hayes CG, Espinoza A, et al. (2002) Effect of dengue-1 antibodies on american dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360: 310-312.
49. Henchal EA, Repik PM, McCown JM, Brandt WE, (1986) Identification of an antigenic and genetic variant of dengue-4 virus from the caribbean. Am J Trop Med Hyg 35: 393-400.
50. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, et al. (2000) Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74: 3020-3028.
51. Brault AC, Kinney RM, Maharaj PD, Green EN, Reisen WK, et al. (2011) Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in aedes aegypti is modulated by a mutation in the 5′ untranslated region and amino acid substitutions in nonstructural proteins 1 and 3. Vector Borne Zoonotic Dis 11: 683-689.
52. Butrapet S, Childers T, Moss KJ, Erb SM, Luy BE, et al. (2011) Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion. Virology 413: 118-127.
53. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, et al. (2004) Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 71: 811-821.
54. Blaney JE Jr, Sathe NS, Goddard L, Hanson CT, Romero TA, et al. (2008) Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4. Vaccine 26: 817-828.
55. Hanley KA, Manlucu LR, Manipon GG, Hanson CT, Whitehead SS, et al. (2004) Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 22: 3440-3448.
56. Yount B, Curtis KM, Baric RS, (2000) Strategy for systematic assembly of large RNA and DNA genomes: Transmissible gastroenteritis virus model. J Virol 74: 10600-10611.
57. Nisalak A, Halstead SB, Singharaj P, Udomsakdi S, Nye SW, et al. (1970) Observations related to pathogenesis of dengue hemorrhagic fever. 3. virologic studies of fatal disease. Yale J Biol Med 42: 293-310.
58. Russell PK, McCown JM, (1972) Comparison of dengue-2 and dengue-3 virus strains by neutralization tests and identification of a subtype of dengue-3. Am J Trop Med Hyg 21: 97-99.
59. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, et al. (2009) Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg 81: 825-833.
60. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. (2009) A prospective nested case-control study of dengue in infants: Rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 6: e1000171.
61. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, et al. (2011) A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29: 3895-3904.
62. Poo J, Galan F, Forrat R, Zambrano B, Lang J, et al. (2010) Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in mexico city: Randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 11: 683-689.
63. Guy B, Saville M, Lang J, (2010) Development of sanofi pasteur tetravalent dengue vaccine. Hum Vaccin 6: 696-705.
64. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, et al. (2005) rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191: 710-718.
65. Guy B, Almond J, Lang J, (2011) Dengue vaccine prospects: A step forward. Lancet 377: 381-382.
66. Tamura K, Nei M, (1993) Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 10: 512-526.
67. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.